Key Details
Price
$30.44PE Ratio
144.95Annual ROE
-14.54%Beta
1.40Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 04, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Corey Rosenbaum - Scotiabank Thomas Flaten - Lake Street Mason Carrico - Stevens Puneet Souda - Leerink Partners Paul Knight - KeyBanc Operator Good afternoon, and welcome to Castle Biosciences Third Quarter 2024 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.26 per share a year ago.
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACG2024--New data at ACG 2024 demonstrates ability of TissueCypher to significantly reduce healthcare costs associated with management of Barrett's esophagus.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces that its executive management is scheduled to present a company overview at three investor conferences in November.
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle will share new data at ASDS supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests.
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Castle Biosciences (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASTRO--Castle will share data at ASTRO24 showing its DecisionDx-SCC test can provide impactful risk stratification in high-risk SCC patient sub-populations.
FAQ
- What is the primary business of Castle Biosciences?
- What is the ticker symbol for Castle Biosciences?
- Does Castle Biosciences pay dividends?
- What sector is Castle Biosciences in?
- What industry is Castle Biosciences in?
- What country is Castle Biosciences based in?
- When did Castle Biosciences go public?
- Is Castle Biosciences in the S&P 500?
- Is Castle Biosciences in the NASDAQ 100?
- Is Castle Biosciences in the Dow Jones?
- When was Castle Biosciences's last earnings report?
- When does Castle Biosciences report earnings?
- Should I buy Castle Biosciences stock now?